Clinical Trial Update: An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 [Phase 2]

View source ↗

Summary

This clinical trial update notes an open-label, long-term follow-up study of SAT-3247 for Duchenne Muscular Dystrophy, including participants from SAT-3247-CL-1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• SAT-3247

Snippet

Sponsor: Satellos Bioscience, Inc. | Conditions: Duchenne Muscular Dystrophy (DMD) | Phase 2 | Status: ENROLLING_BY_INVITATION